Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > LATEST
LATEST
-
REGULATORY LDP Study Group Submits Emergency Proposal to Health Minister, Seeks 5% Drug Price Hike
November 19, 2025
-
BUSINESS Chugai to Absorb Renalys Pharma in Late December
November 19, 2025
-
ORGANIZATION PhRMA Chief Warns Japan Is Losing Its Appeal, Urges End to On-Patent Price Cuts
November 19, 2025
-
BUSINESS Nxera Unveils Restructuring Plan to Return to Profit, 15% Job Cuts in Japan and UK
November 18, 2025
-
BUSINESS Vital KSK to Repurpose Shield’s Iron Deficiency Drug for PAH in Japan
November 18, 2025
-
BUSINESS Lundbeck Files Anti-CGRP Antibody Eptinezumab in Japan
November 18, 2025
-
BUSINESS Nipro Files for Full Approval of Stemirac Cell Therapy
November 18, 2025
-
BUSINESS Dupixent 200 mg Pen Now Available in Japan: Sanofi
November 18, 2025
-
BUSINESS Maruho Licenses Antibiotic Faropenem to China’s CR Gosun
November 18, 2025
-
BUSINESS Otsuka/Ionis’ HAE Prevention Drug Wins CHMP Backing
November 18, 2025
-
BUSINESS Japan’s Big 4 Wholesalers Lower Operating Margin as COVID-19 Windfall Recedes
November 18, 2025
-
REGULATORY Japan Launches Pilot Expert Committee System for Patent Linkage Reviews, Aims to Reduce IP Feuds
November 17, 2025
-
COMMENTARY MOF Autumn Proposals Signal a Shift from Drug Pricing to Cost-Sharing Reform
November 17, 2025
-
REGULATORY Chuikyo Split over Higher Copays under LLP Scheme; Payer Push Meets Provider Caution
November 17, 2025
-
BUSINESS Fuji Stresses No Supply Impact, Denies Patent Allegations over Eylea Biosimilar
November 17, 2025
-
REGULATORY Elrexfio to Escape CEA-Based Price Tweak, Analysis to Resume for Paxlovid
November 17, 2025
-
BUSINESS Kura, Kyowa Kirin Land US FDA Approval for AML Med Komzifti
November 17, 2025
-
BUSINESS Novartis Overhauls Sales Model to Prioritize Solving Regional Treatment Gaps
November 14, 2025
-
REGULATORY Nipro-Samsung Alliance Nears First Approval in Japan with Stelara Biosimilar
November 14, 2025
-
REGULATORY Japan Panel to Review KalVista’s Oral HAE Drug, GSK’s Asthma Med, and More on Nov. 27
November 14, 2025
ページ
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…